Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.
Press Enter β΅ to search evidence
Explore by Goal
"Science is the systematic classification of experience."
- George Henry Lewes
Quick Explanation
Copied
## Evidence status for βCRISPRa/i vs ASO vs gene supplementation for NDDβ
The provided dataset contains **no direct NDD (neurodevelopmental disorder) evidence comparing CRISPRa/i vs ASOs vs gene supplementation**. The only NDD-relevant mechanistic piece here is a **SCN2A (NDD/ASD-related) mouse CRISPRa rescue** study, which supports *one* gene/strategy in *one* model but does **not** establish comparative effectiveness vs ASOs or gene supplementation. See the SCN2A CRISPRa rescue paper for the closest content to the prompt:
Given the mismatch, any βbest evidence rankingβ across **CRISPRa/i vs ASO vs gene supplementation** for NDDs cannot be justified from the provided sources alone.
Long Explanation
1) What the prompt asks vs what the provided data actually supports
Prompt: βBest evidence: CRISPRa/i vs ASO vs gene supplementation for NDD Eβ.
Provided dataset gap: There is no ASO-vs-CRISPR-vs-gene-supplementation comparative NDD evidence in the excerpts you provided.
Closest NDD-adjacent evidence present: A SCN2A (NDD/ASD-related) mouse study using CRISPRa (gene activation) to rescue cortical sensory coding deficits.
Therefore, the only scientifically supportable βbattle-testβ here is: CRISPRa/i feasibility/mechanistic plausibility for one SCN2A-model NDD vs what the dataset lacks (ASOs and gene supplementation comparisons).
2) Tightest evidence in your dataset: SCN2A CRISPRa rescue (mouse sensory circuit)
The model is Scn2a+/β mice (C57BL/6J) with whisker S1 circuit deficits (degraded somatotopy/tuning; broadened tuning curves/maps) and unexpected PV interneuron hypofunction.
Claim supported by extracted results: Rescue of single-unit somatotopy/whisker map activation and improved population decoding; partial PV interneuron functional restoration.
Key caution: the extracted text also indicates translation uncertainty (vector delivery/regulatory differences; systemic brain-wide upregulation variability), scope limits (subset of layers/whisker system), and missing deep behavioral correlation to the neural decoding phenotypes.
Conflicts-of-interest are explicitly disclosed in the extracted record, so any therapeutic enthusiasm should be tempered by that context.
3) Visualizing extracted quantitative endpoints from the SCN2A study
(These plots use only the numeric values present in the provided extracted-data list.)
Source for numeric endpoints plotted above is the extracted-data list in the SCN2A CRISPRa rescue study record.
4) Critical evaluation against the original comparison question (CRISPRa/i vs ASO vs gene supplementation)
4.1 What we can responsibly infer from the dataset
CRISPRa (gene activation) plausibility in one NDD gene/model: The SCN2A CRISPRa rescue study supports that restoring expression of a single haploinsufficient gene (Scn2a) can reverse specific circuit readouts in mice, including after the critical period (in the studyβs experimental framing).
Mechanistic/scaling constraints exist for transcriptional CRISPR tools: Even in bacteria, CRISPRa effectiveness is extremely position/context dependent and not universally transferable across genes/promoters. While that is not a human NDD demonstration, it is a principled warning about generalizing βCRISPRa worksβ across loci/chromatin contexts.
4.2 What we cannot conclude from the dataset
No ASO-vs-CRISPR-vs-gene-supplementation direct NDD comparative evidence: The provided sources do not include ASO efficacy data for NDDs, nor direct βgene supplementationβ trials/comparisons in NDDs, nor head-to-head effectiveness rankings.
So βbest evidence rankingβ is underdetermined: Any attempt to declare CRISPRa/i as superior or inferior to ASOs or gene supplementation would be speculation unsupported by these excerpts.
5) Side-evidence (non-NDD, but relevant to skepticism): transferability/toxicity and design constraints for CRISPRi/a
5.1 Strain-/context-dependent repression magnitude and toxicity (CRISPRi in E. coli)
Across four E. coli strains, CRISPRi repression and toxicity varied by system and strain; dual-gRNA arrays with Lb-dCas12a yielded stronger repression across strains, but toxicity patterns still differed.
Plot: maximum reported fold repression for one representative system across strains (from extracted list).
Numerical values for this plot come from the extracted list under the 2026 cross-strain CRISPRi-transfer study record.
Why this matters to the NDD question: even if CRISPRi/a is effective in a given model, transfer to new contexts (different genes, cell types, chromatin states, delivery routes) can change both efficacy and safety profileβso comparative claims (vs ASO or supplementation) require direct head-to-head evidence, which is missing in the provided dataset.
6) Concrete βbattle-testβ conclusions (grounded in your provided evidence only)
Known from provided evidence: CRISPRa-based endogenous activation of Scn2a can rescue specific neural coding/map deficits in an SCN2A-related mouse model.
Not shown in provided evidence: Any direct comparison among CRISPRa/i vs ASOs vs gene supplementation for NDDs (including which yields best clinical/functional outcomes, durability, or risk profiles).
Methodological skepticism supported by non-NDD CRISPRa/i design studies: CRISPRa/CRISPRi performance is often sharply dependent on target positioning/context, and repression/toxicity can vary strongly across biological contexts (strains; promoters; other systems).
Therefore, the only defensible βbest evidenceβ statement here:CRISPRa for at least one SCN2A-related neural phenotype has experimental rescue support in mice; however, the dataset cannot establish a three-way comparison requested by the prompt.
What would disprove/replace this: full-text evidence in the same dataset that includes (i) NDD human or disease-model ASO data for the relevant targets, (ii) gene supplementation data, and (iii) direct comparative readouts (or at least systematic, target-matched parallel studies).
Extract numeric endpoints from the provided SCN2A and CRISPRi datasets, compute normalized fold-changes vs WT/baseline, and generate Plotly-ready comparison tables and figures for rapid evidence triage.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
βASO and CRISPRa will show the same direction/magnitude of effect across NDD targets because both ultimately reduce a disease pathway.β (Rejected: no ASO data provided; also CRISPR tools are position/context dependent in other systems.)
βGene supplementation will always outperform regulatory (CRISPRa/i) approaches because it provides full protein expression.β (Rejected: no supplementation evidence provided; and CRISPRa rescue already demonstrates pathway-specific restoration in a neural circuit context.)
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion